Literature DB >> 1891063

Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders.

R N Kalaria1, P G Galloway, G Perry.   

Abstract

Amyloid P (AP) component is present in all types of systemic amyloid deposits. Recently, it has been shown to be also present in cerebral amyloid lesions of Alzheimer's disease (AD). In this study, we used immunocytochemical methods to extend these findings at the electron microscope level and characterize the spectrum of AP immunoreactivity in neurofibrillary pathology (NFP) of AD and other neurodegenerative disorders including Down's syndrome (DS), Creutzfeldt-Jakob, Parkinson's, Pick's and diffuse Lewy body diseases and progressive supranuclear palsy. In AD and DS, AP immunoreaction product was evident in all the classical amyloid lesions and NFP in a large sample of all cortical areas examined. The distribution and relative intensity of immunostaining was similar to that of thioflavin S staining in serial sections. In many cases, however, plaques and vessels stained by anti-AP serum were not apparent with thioflavin S. Serial sections immunostained with antiserum to amyloid A, C-reactive protein or to other proteins involved in systemic amyloidoses and the acute phase response showed no evidence of staining in any of the cerebral lesions. Electron microscopy confirmed that AP immunoreactivity was associated with the abnormal filaments characteristic of NFP as well as amyloid fibrils found in plaques and vessels showing congophilic amyloid angiopathy. Plaques of Creutzfeldt-Jakob disease, Pick bodies of Pick's disease, tangles and Lewy bodies in Parkinson's disease and a subpopulation of Lewy bodies in the diffuse Lewy body disease coexistent with AD were also stained. With the exception of vessels in two of the five cases, AP was not detected in age-matched controls. Our observations indicate AP to be a consistent feature of cerebral NFP and amyloid deposits.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1891063     DOI: 10.1111/j.1365-2990.1991.tb00714.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  19 in total

1.  Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation.

Authors:  C J de Haas; E M van Leeuwen; T van Bommel; J Verhoef; K P van Kessel; J A van Strijp
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE.

Authors:  Jorge Ghiso; Yasushi Tomidokoro; Tamas Revesz; Blas Frangione; Agueda Rostagno
Journal:  Hirosaki Igaku       Date:  2010-07-08

3.  Evidence for three loci modifying age-at-onset of Alzheimer's disease in early-onset PSEN2 families.

Authors:  Elizabeth E Marchani; Thomas D Bird; Ellen J Steinbart; Elisabeth Rosenthal; Chang-En Yu; Gerard D Schellenberg; Ellen M Wijsman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-07       Impact factor: 3.568

4.  Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Authors:  Simon E Kolstoe; Basil H Ridha; Vittorio Bellotti; Nan Wang; Carol V Robinson; Sebastian J Crutch; Geoffrey Keir; Riitta Kukkastenvehmas; J Ruth Gallimore; Winston L Hutchinson; Philip N Hawkins; Stephen P Wood; Martin N Rossor; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

Review 5.  The role of beta-amyloid in the development of Alzheimer's disease.

Authors:  K Ii
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

6.  Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.

Authors:  A D Snow; R T Sekiguchi; D Nochlin; R N Kalaria; K Kimata
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

7.  Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains.

Authors:  M A Morán; E J Mufson; P Gómez-Ramos
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

9.  Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease.

Authors:  R N Kalaria; T Golde; S N Kroon; G Perry
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

Review 10.  Siglec receptors and hiding plaques in Alzheimer's disease.

Authors:  Antero Salminen; Kai Kaarniranta
Journal:  J Mol Med (Berl)       Date:  2009-04-24       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.